[ad_1]
IXICO PLC (LON: IXI), John Hall joined Proactive London to discuss two important new contracts they have signed with new biopharmaceutical customers.
The first contract, to finance a preliminary study on Huntington's disease (HD), is worth around £ 2 million and will run for seven years.
The other is a phase 3 study of another rare neurological disease.
Source link
